Clinical ink presents at 1st Annual European BioPharma Obesity Innovation Forum

Clinical ink Chief Medical Officer Dr. Nicholas Alp was an invited speaker at the 1st Annual European BioPharma Obesity Innovation Forum held in Leipzig, Germany, on June 11-12, 2025.  He discussed the value of Clinical ink’s exclusive technology SPUR in addressing poor adherence and retention in obesity clinical trials, by providing a validated assessment of a participant’s adherence risk together with personalized support interventions for participants and investigators.

The conference explored the genetic, clinical, and population science of obesity, and highlighted novel therapeutic strategies to address this global pandemic.  The forum brought together leaders in obesity clinical development, biopharma executives and investors through lectures and panel discussions, to build a community focused on addressing the health challenges of our modern industrialized food ecosystem.